New insight into the regression of cardiac fibrosis.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

3 citing papers in PubMed.

1. The interaction between sarcoplasmic reticulum and mitochondria: a novel mechanism for cardiac arrhythmia.Frontiers in physiology · 2026
   Review
2. Case report: Diagnosis of apical hypertrophic cardiomyopathy that escaped clinical and echocardiographic investigations for twenty years: Reasons and clinical implications.Frontiers in cardiovascular medicine · 2023
   Article
3. And the band played on: persistent fibrosis after unbanding reveals sex-dependent differences in rats.American journal of physiology. Heart and circulatory physiology · 2022
   Article

Corrections and comments

• Comment on
  Mechanisms that limit regression of myocardial fibrosis following removal of left ventricular pressure overload.2022

Authors and funding

2 authors.

Funding

Abstract

PubMed holds no abstract for this paper.

Indexed as